Provided by Tiger Fintech (Singapore) Pte. Ltd.

Haemonetics

64.68
-0.1200-0.19%
Post-market: 64.680.00000.00%16:05 EDT
Volume:683.44K
Turnover:44.20M
Market Cap:3.25B
PE:25.48
High:65.24
Open:64.38
Low:63.45
Close:64.80
Loading ...

Is Haemonetics (NYSE:HAE) Using Too Much Debt?

Simply Wall St.
·
Yesterday

Needham Trims Price Target on Haemonetics to $104 From $108, Keeps Buy Rating

MT Newswires Live
·
Yesterday

Haemonetics Is Maintained at Buy by Needham

Dow Jones
·
Yesterday

CSL is approaching a 5-year low. Is this a buying opportunity?

MotleyFool
·
Yesterday

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe

Zacks
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Business Wire
·
10 Mar

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Mar

J.P. Morgan Remains a Buy on Haemonetics (HAE)

TIPRANKS
·
04 Mar

Haemonetics Names Chan Chief Operating Officer

Dow Jones
·
04 Mar

BRIEF-Haemonetics Announces Executive Leadership Updates

Reuters
·
04 Mar

Haemonetics Names Chief Operating Officer, Chief Commercial Officer

MT Newswires Live
·
04 Mar

Haemonetics announces updates to its Executive Leadership team

TIPRANKS
·
04 Mar

Haemonetics Announces Executive Leadership Updates

THOMSON REUTERS
·
04 Mar

Press Release: Haemonetics Announces Executive Leadership Updates

Dow Jones
·
04 Mar

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

Business Wire
·
03 Mar